buy growth invest pay
strong result robust organ growth order
backlog earn beat better margin perform
expect strong growth continu driven
healthi order backlog higher product
reiter buy rais target price
build organ field order grew good underli growth
hvac fire secur end market order backlog grew y-o-i
organ provid solid visibl sale grew organ
y-o-i adj ebit margin increas
y-o-i adj ep continu oper our/
strong perform sale grew driven strong underli sale
growth adj ebit margin expand driven higher volum
product save cost synergi overal adj ep
y-o-i adj free cash flow increas y-o-i impli
year
convers manag gave adj ep guidanc
low mid-singl digit organ sale growth margin expans share
pure-play build technolog solut provid sale power solut
batteri busi complet compani portfolio transform
pure-play build technolog solut provid favour structur growth
profil driven increas iot adopt believ core portfolio higher
convers lower capit intens better focu margin expans
improv financi flexibl would also posit well benefit strateg
opportun hvac industri
maintain buy rate rais tp valu johnson control pe-bas
valuat methodolog appli target multipl averag
forward pe build effici peer appli multipl forward
adj net incom arriv fair valu equat revis target
price vs earlier new target price impli upsid
reiter buy rate see visibl path double-digit net incom
continu oper growth compound-annual-growth-rate manag deliv
oper execut synergi target improv gener
hsbc secur capit market india privat
global co-head industri research
employ non-u affili hsbc secur usa inc
registered/ qualifi pursuant finra regul
report must read disclosur analyst certif
disclosur appendix disclaim form part
issuer report hsbc bank plc
view hsbc global research
year
board member
employe cost revenu
ghg intens energi intens measur kg kwh respect revenu usd
note price close
year
base hsbc ep dilut
flow oper
flow invest
chang net debt
ratio growth per share analysi
year
cf operations/net debt
control increl
build field order sale organ growth y-o-i
chang estim
make chang estim follow result guidanc util
proce sale power solut batteri busi
expect sale organ sale growth new
ep manag guidanc driven organ sale growth
margin expans share repurchas
new ep driven organ sale growth margin expans
share repurchas introduc ep driven
organ sale growth margin expans share repurchas
johnson control chang estim
valuat risk
valu johnson control pe-bas valuat methodolog appli target multipl
averag forward pe build effici peer plc us
nr ir us nr schneider electr su fp cp
appli multipl forward adj net incom arriv fair valu
equat revis target price vs earlier new target price
impli upsid reiter buy rate see visibl path double-digit net
incom continu oper growth forecast compound-annual-growth-rate manag
deliv oper execut synergi target improv gener
manag abl realis state synergi target target
cost benefit synergi product howev synergi realis depend
well compani execut integr miss state target could
downturn us non-residenti market could impact earn neg
compani exposur commerci institut market materi deterior
us non-residenti market could put downward pressur forecast
compani cut long-term target could dent manag credibl impact
